News Article | December 12, 2016
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today that it has appointed Linda Kozick to its board of directors. Linda brings more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology, specializing in immuno-oncology. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a90c227f-b0d7-49cf-993c-8d76d11a5177. "We are delighted to welcome Linda to the FLX Bio board as the company advances its growing immuno-oncology and targeted oncology pipeline. Linda’s leadership in developing commercial strategies for key immuno-oncology therapies makes her an ideal candidate to help FLX Bio navigate clinical and commercial opportunities with our strong pipeline of product candidates,” said Dr. Brian Wong, CEO of FLX Bio. “FLX Bio has a strong discovery platform and has built a highly differentiated pipeline of immuno-oncology and targeted oncology compounds,” said Ms. Kozick. “I am delighted to join the FLX Bio Board of Directors to work alongside FLX Bio’s outstanding executive team, Board of Directors and Scientific Advisory Board members to realize the company’s goal of bringing best-in-class, next generation oncology therapies to patients." Ms. Kozick recently retired from Bristol-Myers Squibb (BMS) after 26 years. Most recently, she served as Vice President and Head of Immuno-Oncology/Oncology Product & Portfolio Strategy, and Opdivo and Yervoy Life Cycle Management. Prior to that, Ms. Kozick held several key positions including Vice President, Commercial Lead for Opdivo and Immuno-Oncology Platform Strategy, and was instrumental in establishing BMS’s International Immuno-Oncology Network (II-ON). Ms. Kozick received her Bachelor of Science and Master of Science degrees from Upstate Medical Center, and her Master’s in Business Administration from Chapman University. Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights in cancer biology and the immune system to discover and develop novel oral medicines that activate immune responses to eliminate cancer cells. Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG) and Celgene, FLX Bio has assembled a management and R&D leadership team with a proven track record of success and an advisory group and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.
Fiese B.H.,University of Illinois at Urbana - Champaign |
Winter M.A.,University of Rochester |
Botti J.C.,Upstate Medical Center
Child Development | Year: 2011
Family mealtimes have the potential to promote healthy child development. This observational study of 200 family mealtimes examined the relation between child health in a group of children (ages 5 to 12) with persistent asthma and 3 dimensions of mealtime interaction: Action, Behavior Control, and Communication. Percent time spent in Action and Positive Communication varied by asthma severity, child quality of life, and sociodemographic variables. Positive communication during mealtimes predicted child quality of life. Significant interactions between demographic variables and behavior control suggested that higher levels of behavior control affected child quality of life in the context of lower maternal education. Guidance is offered for practitioners and policy makers toward promoting healthy family mealtimes as a public health priority. © 2011 The Authors. Child Development © 2011 Society for Research in Child Development, Inc.
Asselin B.L.,University of Rochester |
Devidas M.,University of Florida |
Wang C.,University of Florida |
Pullen J.,University of Mississippi Medical Center |
And 4 more authors.
Blood | Year: 2011
The Pediatric Oncology Group (POG) phase 3 trial 9404 was designed to determine the effectiveness of high-dose methotrexate (HDM) when added to multiagent chemotherapy based on the Dana-Farber backbone. Children with T-cell acute lymphoblastic leukemia (T-ALL) or advanced lymphoblastic lymphoma (T-NHL) were randomized at diagnosis to receive/not receive HDM (5 g/m2 as a 24-hour infusion) at weeks 4, 7, 10, and 13. Between 1996 and 2000, 436 patients were enrolled in the methotrexate randomization. Five-year and 10-year event-free survival (EFS) was 80.2% ± 2.8% and 78.1% ± 4.3% for HDM (n = 219) versus 73.6% ± 3.1% and 72.6% ± 5.0% for no HDM (n = 217; P = .17). For T-ALL, 5-year and 10-year EFS was significantly better with HDM (n = 148, 5 years: 79.5% ± 3.4%, 10 years: 77.3% ± 5.3%) versus no HDM (n = 151, 5 years: 67.5% ± 3.9%, 10 years: 66.0% ± 6.6%; P = .047). The difference in EFS between HDM and no HDM was not significant for T-NHL patients (n = 71, 5 years: 81.7% ± 4.9%, 10 years: 79.9% ± 7.5% vs n = 66, 5 years: 87.8% ± 4.2%, 10 years: 87.8% ± 6.4%; P = .38). The frequency of mucositis was significantly higher in patients treated with HDM (P = .003). The results support adding HDM to the treatment of children with T-ALL, but not with NHL, despite the increased risk of mucositis. © 2011 by The American Society of Hematology.
Bied A.M.,Upstate Medical Center |
Kim J.,Emory University |
Schwartz T.L.,Emory University
Expert Review of Clinical Pharmacology | Year: 2015
The selegiline transdermal system (STS) is the first antidepressant transdermal medication approved by the US FDA for the treatment of major depressive disorder. Its unique antidepressant delivery system allows for steady release of selegiline over 24 h with minimal fluctuation in drug serum levels. It is able to deliver high enough central nervous system concentrations required for an antidepressant effect without substantially inhibiting Monoamine oxidase-A in the gastrointestinal and hepatic system, thereby reducing the risk of tyramine hypertensive crises especially at the lowest doses. Patient adherence theoretically could be improved due to ease of use and once-daily dosing when compared to oral counterparts' need for multiple daily doses. Clinical trials have established that doses between 6 and 12 mg over 24 h have been effective for major depressive disorder and tolerated among patients. Episodes of hypertensive crisis with STS have been minimally reported thus far. Overall, STS appears to be an effective agent for major depressive disorder when held to regulatory standards and post marketing analyses. This paper reviews the pharmacologic characteristics of STS and results of studies investigating its clinical efficacy and safety. © 2015 Taylor & Francis.
Kaul P.,University of Kentucky |
Kaul P.,Upstate Medical Center |
Passafiume J.,University of Kentucky |
Sargent C.R.,University of Kentucky |
O'Hara B.F.,University of Kentucky
Behavioral and Brain Functions | Year: 2010
Background: A number of benefits from meditation have been claimed by those who practice various traditions, but few have been well tested in scientifically controlled studies. Among these claims are improved performance and decreased sleep need. Therefore, in these studies we assess whether meditation leads to an immediate performance improvement on a well validated psychomotor vigilance task (PVT), and second, whether longer bouts of meditation may alter sleep need.Methods: The primary study assessed PVT reaction times before and after 40 minute periods of mediation, nap, or a control activity using a within subject cross-over design.This study utilized novice meditators who were current university students (n = 10). Novice meditators completed 40 minutes of meditation, nap, or control activities on six different days (two separate days for each condition), plus one night of total sleep deprivation on a different night, followed by 40 minutes of meditation.A second study examined sleep times in long term experienced meditators (n = 7) vs. non-meditators (n = 23). Experienced meditators and controls were age and sex matched and living in the Delhi region of India at the time of the study. Both groups continued their normal activities while monitoring their sleep and meditation times.Results: Novice meditators were tested on the PVT before each activity, 10 minutes after each activity and one hour later. All ten novice meditators improved their PVT reaction times immediately following periods of meditation, and all but one got worse immediately following naps. Sleep deprivation produced a slower baseline reaction time (RT) on the PVT that still improved significantly following a period of meditation. In experiments with long-term experienced meditators, sleep duration was measured using both sleep journals and actigraphy. Sleep duration in these subjects was lower than control non-meditators and general population norms, with no apparent decrements in PVT scores.Conclusions: These results suggest that meditation provides at least a short-term performance improvement even in novice meditators. In long term meditators, multiple hours spent in meditation are associated with a significant decrease in total sleep time when compared with age and sex matched controls who did not meditate. Whether meditation can actually replace a portion of sleep or pay-off sleep debt is under further investigation. © 2010 Kaul et al; licensee BioMed Central Ltd.
Ray T.,Ramakrishna Vedanta Ashrama of Phoenix |
Ray T.,Upstate Medical Center
F1000Research | Year: 2013
This article offers an explanation for the apparent lack of Na, K-ATPase activity in parietal cells although ouabain has been known to inhibit gastric acid secretion since 1962. The gastric H, K-ATPase (proton-pump) seems to be acting in altered states, thus behaving like a Na, K-ATPase (Na-pump) and/or Ca-ATPase (Ca-pump) depending on cellular needs. This conclusion is based on the following findings. First, parietal cell fractions do not exhibit Na, K-ATPase activity at pH 7.0 but do at pH 8.5. Second, the apical plasma membrane (APM) fraction exhibits a (Ca or Mg)-ATPase activity with negligible H, K-ATPase activity. However, when assayed with Mg alone in presence of the 80 k Da cytosolic proton-pump activator (HAF), the APM fraction reveals remarkably high H, K-ATPase activity, suggesting the observed low affinity of Ca (or Mg)-ATPase is an altered state of the latter. Third, calcium (between 1 and 4 μM) shows both stimulation and inhibition of the HAF-stimulated H, K-ATPase depending on its concentration, revealing a close interaction between the proton-pump activator and local Ca concentration in gastric H, K-ATPase function. Such interactions suggest that Ca is acting as a terminal member of the intracellular signaling system for the HAF-regulated proton-pump. It appears that during resting state, the HAF-associated H, K-ATPase remains inhibited by Ca (>1 μM) and, prior to resumption of acid secretion the gastric H, K-ATPase acts temporarily as a Ca-pump for removing excess Ca from its immediate environment. This conclusion is consistent with the recent reports of immunochemical co-localization of the gastric H, K-ATPase and Ca-ATPase by superimposition in parietal cells, and a transitory efflux of Ca immediately preceding the onset of acid secretion. These new perspectives on proton-pump function would open new avenues for a fuller understanding of the intracellular regulation of the ubiquitous Na-pump. © 2013 Ray T.
McDermott S.,University of South Carolina |
Turk M.A.,Upstate Medical Center
Disability and Health Journal | Year: 2011
The concept of disability has medical, functional, and social components. We review the frameworks for the definition of disability and endorse a multidimensional approach that is parsimonious and has utility for epidemiology. We need to be able to count people with disabilities to quantify service and support needs, to study the life course of people with specific disabilities, and to accurately target prevention strategies. In addition, it is important to have some precise measures of disability so comparisons can be made between impairments, to identify disparities and differences, and to measure changes over time. We need to ensure that there is no confusion about cause and effect (attributing associated conditions as outcomes of disability when they are in fact the cause of the functional limitation) and that comparisons to people without disabilities are fair. If people who experience disability due to a condition such as obesity are included in the case definition of disability, then we cannot say people with disability are more likely to be obese. The credibility of disability epidemiology and the disability field is at stake. © 2011 Elsevier Inc. All rights reserved.
Klosterman T.,Upstate Medical Center |
Tatum S.A.,Upstate Medical Center
Current Opinion in Otolaryngology and Head and Neck Surgery | Year: 2015
Purpose of review To discuss the current surgical management of macroglossia. Recent findings Traditional surgical management of severe macroglossia has been with anterior wedge or keyhole resection. Long-term follow-up has been limited, and only recently have assessments been done regarding functional and aesthetic outcomes. New methods including double stellate and combination approaches have shown promise, though with limited case size reports. Addressing macroglossia in three dimensions may be the most effective way of achieving positive positional, speech and aesthetic outcomes, but comparative studies are lacking. Other causes of macroglossia, such as vascular malformations, can be managed with less aggressive measures such as laser and radio-frequency ablation. Summary The aggressiveness of the management should match the severity of the symptoms. The anterior wedge resection and modified keyhole incisions are the most well studied operative strategies. Short and long-term outcome data are limited, and neither method is definitively superior. Less aggressive measures are options for less severe macroglossia. Surgical management of macroglossia should be tailored to each individual patient and in accordance to surgeon experience and expertise. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Bratslavsky G.,Upstate Medical Center |
Cheng J.-S.,Massachusetts General Hospital
Urology | Year: 2015
Objective To describe a case of robotic-assisted radical nephrectomy (RARN) with level III retrohepatic vena caval tumor thrombectomy (11 cm) and extended retroperitoneal lymph node dissection (RPLND) for renal cell carcinoma (RCC). Materials and Methods A 52-year-old woman with a large right renal mass, 11-cm (level III) inferior vena cava (IVC) thrombus, with a negative metastatic workup presented to our clinic and was consented to undergo RARN. Intraoperative ultrasound confirmed the presence of tumor thrombus. After the division of the renal artery, control of the vena cava above and below the tumor thrombus as well as contralateral renal vein was obtained. A cavotomy was performed, the thrombus was removed, and the cavotomy was repaired. Additionally, an extended RPLND was performed with robotic assistance. Results Total operative time was 6 hours and 6 minutes. Estimated blood loss was 1200 cc. The final pathology demonstrated an 8.5-cm, Fuhrman grade 3, clear cell RCC with sarcomatoid features and negative surgical margins. All 44 lymph nodes removed (hilar, paracaval, precaval, retrocaval, interaortocaval, and preaortic) were negative. Final staging was pT3b, N0, M0. The patient was discharged to home 36 hours postoperatively and experienced no perioperative or postoperative complications. Conclusion RARN with retrohepatic (level III) vena caval tumor thrombectomy and extended RPLND is technically feasible and has potential benefits. Robotic assistance may allow for improved intracorporal repair of the IVC and shortened recovery time, while maintaining oncologic principles. © 2015 Elsevier Inc.
News Article | December 9, 2016
Mediaplanet today announces distribution of the latest edition of “Transplants,” a cross-platform campaign that raises awareness for organ transplantation while encouraging readers to sign up as an organ donor for the 123,000 people in the United States who are currently waiting for a lifesaving organ transplant. An organ donor can save up to 8 saves through organ donation and enhance many others through tissue donation, however thousands die every year waiting for a donor organ that never comes. Throughout the campaign we look at the impact an organ and/or bone marrow donation can make while highlighting the best resources and services available that are working to make sure we continue to see progress in the transplant field. Actress & Organ Donation Advocate, Katherine Heigl, speaks out about her family’s tragic loss of her brother and the compassionate act that saved four lives in the print and digital campaign. In an exclusive interview with Mediaplanet, Katherine and her mother, Nancy Heigl, share their story in hopes to continue to spread awareness on organ donation. “We knew that a young man got his heart and two people got their sight back,” she says. “Who received them didn’t matter other than that they saved other lives.” The family’s act gave 4 different people another chance and while the decision was tough they knew it was the right one. “Even in the midst of unimaginable pain and sorrow, I knew that we needed to have as much compassion for others as we had for ourselves”, Nancy Heigl adds. The print component of “Transplants” is distributed within the December 9th issue of USA Today in New York, LA, Boston, Chicago, Washington D.C./Baltimore, St. Louis, and Philadelphia with a circulation of approximately 250,000 copies and an estimated readership of 750,000 readers. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here. This edition of “Transplants” was made possible with the support of the American Society of Transplantation, UNOS, Donate Life, UPMC, UW Health, Katherine & Nancy Heigl, DKMS, University of Utah Health Care, SUNY Upstate Medical Center, American College of Cardiology, Chris Klug Foundation, University Colorado Health, Syncardia, Transplant Solutions and many more. About Mediaplanet: Mediaplanet is the leading independent publisher of content-marketing campaigns covering a variety of topics and industries. We turn consumer interest into action by providing readers with motivational editorial, pairing it with relevant advertisers, and distributing it within top newspapers and online platforms around the world.